The short version

The four phrases below are not one universal rating system. A U.S. cosmetic claim, an EU/EEA cosmetic claim, an OTC drug claim and a paid advertisement can carry different duties. The FTC evaluates express and implied claims from the overall ad and intended audience, while EU Regulation 655/2013 requires cosmetic claims to be truthful, supported, honest and fair in the relevant market (EUR-Lex Regulation 655/2013).

The practical question is not “does this badge sound reassuring?” It is: what product was tested, against what, for which endpoint, for how long, and under which market’s rules?

“Clinically proven” or “clinically tested”

These are evidence-bearing advertising phrases. FTC guidance says objective claims need a reasonable basis before dissemination, and that a claim implying clinical proof carries the implication an advertiser must substantiate (FTC Health Products Compliance Guidance). For health-related claims, FTC describes randomized, controlled human clinical testing as the form experts generally require, while also pointing to sample size, duration, endpoint, controls, analysis and relevance.

That does not make a bottle FDA-approved. FDA says ordinary cosmetics and their ingredients generally do not require premarket approval, and it does not require companies to submit a particular test package before marketing (FDA authority over cosmetics). An isolated-ingredient study also does not automatically substantiate a finished formula containing other ingredients (FTC Health Products Compliance Guidance).

For EU/EEA cosmetics, Regulation 655/2013 says evidence should be adequate, verifiable, relevant to the product and benefit, and consistent with the product information file; ingredient properties cannot simply be transferred to a finished product without adequate support (Regulation 655/2013).

“Dermatologist tested”

The phrase does not tell you, by itself, who participated, how many people were included, what the dermatologist did, whether the test measured safety, tolerability or efficacy, or whether there was a control. No exact federal definition for this phrase was located in the FDA sources checked; that is an evidence/documentation gap, not proof that the phrase has no legal meaning in every jurisdiction (FDA authority over cosmetics; FTC Health Products Compliance Guidance).

Treat it as a request for the protocol and report, not as “dermatologist recommended,” FDA-cleared, independently tested or clinically effective. If a brand gives no details, the responsible conclusion is that the phrase alone does not answer those questions.

“Hypoallergenic”

In the United States, FDA says “hypoallergenic” is a manufacturer claim that a product produces fewer allergic reactions than other cosmetics, but there are no Federal standards or definitions governing the word and manufacturers do not have to submit substantiation to FDA (FDA: “Hypoallergenic” cosmetics).

That is U.S. federal context, not a universal statement about every market. It also is not allergy-proof language: FDA says cosmetics can cause reactions and that “hypoallergenic,” “fragrance-free” and “for sensitive skin” have no federal standard or definition in the U.S. (FDA Allergens in Cosmetics). You cannot infer that the product contains no fragrance or preservatives, or that it will suit a particular person, from this word alone (FDA: “Hypoallergenic” cosmetics).

“Non-comedogenic”

This label does not, by itself, disclose what finished-product test, definition or endpoint—if any—was used. It is not a promise that no individual will break out, and it does not mean that the product treats acne. A systematic review of OTC dermatologic marketing terms reported that “non-comedogenic” had varied clinical utility and was not regulated by a governing body in the literature it reviewed (Boozalis and Patel, Johns Hopkins record). That is literature context, not a universal legal conclusion for every country.

Ask for the finished-product test, population, exposure duration, comparator, lesion endpoint, formula and market version before treating the word as useful evidence. An ingredient’s reputation or a comedogenicity number is not the same as a test of the finished bottle (Boozalis and Patel, Johns Hopkins record; Regulation 655/2013).

Why the label can still surprise you

In a cohort/content analysis of 174 best-selling whole-body moisturizers, researchers found that 18 of 40 products self-declared “fragrance free” had at least one fragrance cross-reactor or botanical ingredient in the authors’ database. The audit did not expose people to the products and did not prove that any product caused an allergy (Xu et al., JAMA Dermatology full text). That result is not a reason to declare every “fragrance free” label false; it is a reason to read the current ingredient panel and not turn a front-label word into an individual safety prediction.

The audit in one line

Each phrase quietly leaves out a noun: which product, compared with what, for which endpoint, over what duration, and what did “tested” involve? That missing protocol is the non-obvious content of the claim. Neither a reassuring word nor a study of a different ingredient or formula can answer for the bottle in your hand (FTC Health Products Compliance Guidance; Regulation 655/2013).

Sources

Researched, not tested. We did not test a product, audit a brand’s private claim file or reproduce a clinical study for this page. This is general information, not medical or legal advice.